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BACKGROUND
Food allergy—particularly immunoglobulin E (IgE)-mediated food
allergy—is now a global public health problem. It results in
considerable morbidity, healthcare utilisation, and impairment in
quality of life.1–6 Food allergy reactions range in severity from
relatively mild features to life-threatening anaphylaxis.2, 3 Esti-
mates of the prevalence of food allergy vary, but overall lifetime
prevalence has been estimated as affecting up to 7% of children
and 6% of adults.4, 5
Careful avoidance of offending foods is the mainstay preventive
strategy for food allergy.2, 3 Accurate diagnosis is essential in order
to provide appropriate, potentially life-saving advice on how to
prevent and manage reactions. This will also help to prevent
unwarranted dietary restrictions.2, 3 The diagnosis of food allergy
is typically based on a combination of clinical history and an
objective marker of allergic sensitisation, namely, skin prick tests
(SPT) and/or immunoassays of serum-speciﬁc IgE levels. While
these approaches have reasonable sensitivity, they have sub-
optimal speciﬁcity and are in general poorly predictive of the
severity of reactions. Further diagnostic conﬁrmation with a
double-blinded placebo-controlled food challenge (DBPCFC)—the
gold standard diagnostic test—is therefore often required.2, 3, 7
DBPCFC is however costly, technically challenging, time-consum-
ing, labour-intensive, and associated with important safety risks as
the procedure can trigger anaphylaxis.2, 3, 8 Nevertheless,
although risky, DBPCFCs offer a reliable diagnosis, which in turn
increases patients’ quality of life.9
The limitations of conventional methods for diagnosing food
allergy have stimulated promising developments in molecular-
based diagnostic techniques, collectively referred to as
component-resolved diagnosis (CRD).2, 8, 10 Molecular diagnosis
of food allergy involves examining the speciﬁc proteins in foods,
primarily at the molecular level.8 In this case, rather than providing
a summary of all the allergen proteins in a particular food (e.g.,
peanuts), molecular-based methods quantify the individual
proteins within a food that may be responsible for allergic
reactions.8 In CRD, speciﬁc IgE responses are evaluated against
individual allergenic molecules or the epitopes of those allergens.
Therefore, CRD techniques have the potential to enhance the
speciﬁcity and sensitivity of serum-speciﬁc IgE responses to foods.
They may also: facilitate our ability to determine speciﬁc food
allergy phenotypes; help improve compilation of a patient-tailored
risk proﬁle to speciﬁc food allergens, given that IgE antibodies
to food molecules vary from patient to patient and also
geographically; and boost the ability to distinguish between
primary and secondary sensitisers.2, 8, 10 Importantly, in CRD
approaches, diagnosis can be undertaken either in single test
formats or in a microarray by simultaneously evaluating a range of
allergens.2, 8, 10
There is now a substantial body of evidence on using CRD to
diagnose food allergy, which needs to be synthesised in order to
generate robust estimates of diagnostic accuracy and assess cost-
effectiveness in comparison with conventional approaches.
Furthermore, a synthesis of the underlying evidence will help to
inform deliberations on whether and how CRD should be
deployed for (i) diagnosing food allergy, and (ii) assessing patient
risk through the prediction of food allergy severity (i.e., the
likelihood of life-threatening anaphylaxis as opposed to relatively
mild features) across differing healthcare service contexts.
AIMS
We seek to identify, critically appraise, and undertake meta-
analyses of studies using CRD for the diagnosis of food allergy.
Speciﬁcally, we aim to:
a. Determine the accuracy (i.e., sensitivity, speciﬁcity, positive
and negative predictive values) of CRD for diagnosis of cow’s
milk, wheat, egg, peanut, soy, tree nuts, ﬁsh, and shellﬁsh
allergy.
b. Summarise the evidence on the cost and cost-effectiveness of
CRD in comparison with conventional techniques for the
diagnosis of cow’s milk, wheat, egg, peanut, soy, tree nuts,
ﬁsh, and shellﬁsh allergy.
c. Summarise the evidence on the ability of CRD to predict the
severity of cow’s milk, wheat, egg, peanut, soy, tree nuts, ﬁsh,
and shellﬁsh allergy.
METHODS
The Preferred Reporting Items for Systematic Review and Meta-Analysis
Protocols (PRISMA-P) checklist has been used to guide the reporting of this
protocol.11
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Study eligibility criteria
Types of studies. We will include prospective, retrospective, and cross-
sectional studies. Studies must have sufﬁcient data to calculate the
relevant diagnostic measures, including sensitivity, speciﬁcity, and positive
and negative predictive values. All studies must have a deﬁned study
population, with either consecutive or random sampling of participants. If
the recruitment technique used to select participants is not indicated in a
study, we will contact the authors to request further information about
their study. In the case we do not receive a response from authors, we will
include such study and undertake relevant sensitivity analyses to assess
their impact on the overall test performance.
Types of participants. We will include studies that have examined patients
with suspected food allergy of any age.
Target conditions. We will include studies examining the CRD diagnostic
accuracy of allergenic molecules of the eight most common IgE-mediated
food allergies, namely, cow’s milk, egg, wheat, soy, peanut, tree nuts
(including, but not limited to hazelnut, walnut, cashew, brazil nut,
pistachio, almond), ﬁsh (including, but not limited to cod and carp), and
shellﬁsh (shrimp).
Index test. We will include studies that have utilised molecular diagnostic
techniques either based on allergenic molecules (using CRD) or the
epitopes of those allergens (using epitope mapping or proﬁling).
Reference standard. We will use the DBPCFC as the gold standard for
evaluating test accuracy. We will include studies in which DBPCFC has
been undertaken in at least 50% of subjects in order to provide sufﬁcient
sample to strengthen the internal validity of each study. Secondarily, with
regard to evaluating impact on decision-making, we will also compare CRD
performance with current standard practice (i.e., clinical assessment plus
SPT and/or speciﬁc IgE).
Exclusion criteria. We will exclude the following reports: reviews,
discussion papers, non-research letters and editorials; qualitative studies;
case studies, case series; animal studies; and studies that include
participants on the basis of a positive food allergy test result.
Search strategy
We will search the following databases from 1 January 2000 to 31 July
2016 for studies of diagnostic tests for food allergy: AMED (Ovid), CAB
Abstracts (Ovid), the Cochrane Library, CINAHL (EBSCO), Embase (Ovid),
Global Health (Ovid), MEDLINE (Ovid), PsycINFO (Ovid), Web of Science
Core Collection (Thomson Reuters), WHO’s Global Health Library, and the
Health Economic Evaluations Database. Although CRD methods for food
allergy were already described in the 1990s,12 their application for food
allergy diagnosis came into force fully in the 2000s, hence we have chosen
the beginning of 2000 as a reasonable starting time for the literature
search. We will obtain additional references by searching the references
cited in identiﬁed studies, by contacting international experts and authors
who have published in the ﬁeld (we have compiled a preliminary list of
experts to contact), and by searching the ISI Conference Proceedings
Citation Index. We will search trial registries, such as Current Controlled
Trials (http://www.controlled-trials.com), ClinicalTrials.gov (http://www.
clinicaltrials.gov), the Australian and New Zealand Clinical Trials Registry
(http://www.anzctr.org.au), and WHO’s International Clinical Trials Registry
Platform (http://www.who.int/ictrp/en/) to identify ongoing studies. Using
the Ovid interface for MEDLINE, we have developed a search strategy
(Appendix 1) to identify and retrieve relevant studies for the review and
this will be adapted in searching the other databases. There are no
language restrictions for included studies: literature in languages other
than English will be translated where possible, and any literature that we
are unable to translate will be reported.
Data management and selection process
We will export retrieved records from all databases to Endnote Library for
study screening, de-duplication, and management of the retrieved records.
Titles and abstracts of retrieved records will be screened and full text
copies of potentially eligible studies will be assessed by two independent
reviewers; a third reviewer will arbitrate any discrepancies.
Data extraction
We will develop and pilot a data extraction form that will be used to collect
relevant data from eligible studies. Two reviewers will independently
extract relevant study data from included studies onto the form; a third
reviewer will arbitrate any discrepancies.
Data items
We will produce descriptive tables to tabulate and summarise relevant
data from included studies. We will capture the following minimum set of
data items from included studies: study author, country of study, year of
publication, type of study design, study size, source of study population,
type of food allergy, type of CRD used to diagnosed food allergy, key
summary results of diagnostic accuracy, any reported risk assessment
measures. For cost-effectiveness analyses, the following minimum set of
data items will be extracted: competing tests analysed, economic study
design type, economic perspective, test cost, measured outcome and its
value, and future costs of the outcome and the test. We will use the
PRISMA checklist to guide the reporting of the systematic review.13
Quality assessment of studies
Risk of bias in eligible studies will be assessed by two reviewers; a third
reviewer will arbitrate any discrepancies. We will assess the quality of
included studies using the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) tool.14 We will quality assess the economic studies
using the Drummond criteria.15 For all studies, we will quality assess the
following components of each study: patient population; index test used
and interpretation; type of reference standard used; and data analysis. The
quality of each of these components will be graded as high, moderate, or
low.
Data syntheses
As a ﬁrst step of synthesising the evidence from included studies, we will
graph the diagnostic test accuracy of the individual studies. The paired
results for sensitivity and speciﬁcity will be plotted as receiver operating
characteristic (ROC) curves, using these to highlight the covariation
between the sensitivity and speciﬁcity in the individual studies. These
initial graphical representations will also enable visual assessment of the
variation between studies and facilitate subgroup analyses for exploring
the effect of certain characteristics (e.g., sex, age, country/geographical
region) on test performance. Expectedly, the cut-offs used to deﬁne test
positivity may vary across studies; therefore, to summarise and compare
the accuracy of the test across studies for each endpoint, we will employ
the hierarchical summary ROC (HSROC) model.16 Through the inclusion of
random effects, the HSROC model accounts for the variability across
studies. The model uses study-speciﬁc estimates of the true positive rate
(sensitivity) and the false positive rate (1—speciﬁcity) to estimate a
summary ROC curve. Where studies have used a common or similar cut-off
and have analysed populations with similar characteristics, we will use
parameter estimates from the models to compute summary sensitivities
and speciﬁcities with 95% conﬁdence intervals. We will investigate
between-study heterogeneity with the HSROC model using the following
covariates to evaluate the association between study (type of study design,
sampling methods employed, country of origin, cut-offs for test positivity)
and patient characteristics (age, sex, disease severity) and test perfor-
mance. The results from the quality assessment will be used to undertake
sensitivity analyses by evaluating whether the quality of studies (low,
medium, high quality) has any impact on the overall conclusion. All
analyses will be performed with Stata version 14.0 (StataCorp LP, College
Station, TX, USA). A narrative synthesis of the data will also be undertaken
and will be the approach particularly employed in summarising the
evidence pertaining to risk prediction and cost-effectiveness.
Publication bias
We will evaluate publication bias by using funnel plots and Begg and
Egger tests.17, 18
Evaluating conﬁdence in the overall evidence
We will evaluate the strength and quality of the overall evidence by using
the GRADE (Grading of Recommendations Assessment, Development and
Evaluation) approach.19 The GRADE system is useful for evaluating the
quality of evidence and strength of recommendations.19
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Protocol registration
A detailed protocol for the review will be registered with the International
Prospective Register of Systematic Reviews (PROSPERO): http://www.crd.
york.ac.uk/prospero/ prior to commencing the review.
DISCUSSION
The major allergens in different food allergies have now been measured
using the CRD technique across different settings.8, 10, 20–23 For example,
Ara h 2 for peanut allergy, omega-5-gliadin for wheat allergy, rGly m 4 for
soy milk allergy, and a number of tree nuts, fruits, vegetables, and ﬁsh have
now been established.8, 10, 20–23 Despite the potential of CRD in improving
diagnosis of food allergy, a number of important questions regarding its
clinical application remain. These include a clear determination of whether
these tests offer beneﬁt over-and-above existing procedures and, if so,
where in the clinical pathway CRD ﬁts—whether as a screening tool or
conﬁrmatory method; an assessment of the impact of CRD diagnosis on
the risk proﬁle of patients; and a clear appreciation of the cost implications
for its use in clinical practice in comparison with current approaches.
Addressing these questions will provide a strong basis for deciding on the
signiﬁcance of CRD for the diagnosis of food allergy in the clinical setting.
This is the ﬁrst systematic review of the diagnostic accuracy of CRD for
food allergy: in addition to synthesising the evidence on the diagnostic
measures of the eight most common food allergies (cow’s milk, egg,
wheat, soy, peanut, tree nuts, ﬁsh, and shellﬁsh), we will, where possible,
undertake risk assessment of CRD on patients, and summarise the
estimates of the cost-effectiveness of CRD for diagnosing these food
allergies.
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